Every Form 4 that Artiva Biotherapeutics, Inc. (ARTV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ARTV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARTV filings page.
Artiva Biotherapeutics, Inc. (ARTV) Chief Executive Officer and director Fred Aslan sold 23,463 shares of common stock on October 6, 2026, at a weighted average price of $7.1977 per share; individual sale prices ranged from $6.92 to $7.36. The sale was made pursuant to a Rule 10b5-1 plan adopted on May 13, 2026. His reported direct holdings after the transaction were 1,519,606 shares.
Christopher Horan, Artiva Biotherapeutics, Inc. (ARTV)’s Chief Tech Operations Officer, sold 10,340 shares of common stock on October 5, 2026, at $6.8372 per share. He held 312,744 shares directly following the sale. The transaction was automatic under the issuer’s sell-to-cover policy to satisfy tax withholding obligations connected with the vesting and release of restricted stock units, and was not at his discretion.
Artiva Biotherapeutics, Inc. COO, CLO and Compliance Officer Jennifer Bush sold 8,370 shares of common stock on October 5, 2026, at $6.8372 per share, leaving her with 366,159 shares held directly. The sale was automatic under the issuer’s sell-to-cover policy to meet tax withholding obligations related to the vesting and release of restricted stock units, and was not at her discretion. No Rule 10b5-1 plan is reported.
Artiva Biotherapeutics, Inc. (ARTV) Chief Medical Officer Subhashis Banerjee sold 1,099 common shares on October 5, 2026, at $6.8372 per share. The sale was automatic under the issuer’s sell-to-cover policy to meet tax-withholding obligations tied to the vesting and release of restricted stock units; it was not at Banerjee’s discretion. He held 169,848 shares directly after the sale. No Rule 10b5-1 plan is reported.
Artiva Biotherapeutics, Inc. CEO and director Fred Aslan reported selling 61,696 common shares on October 5, 2026, at $6.8372 per share. The sale was automatic under the issuer’s sell-to-cover policy to meet tax withholding obligations connected with vesting and release of restricted stock units, and was not at his discretion. He directly held 1,543,069 shares after the sale. No Rule 10b5-1 plan is reported.
Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Executive Officer Fred Aslan received new equity awards on September 15, 2026. He was granted 110,000 shares of Common Stock as a restricted stock unit award under the company’s 2024 Equity Incentive Plan, increasing his direct Common Stock holdings to 1,604,765 shares after the grant.
He was also granted an option to acquire 315,000 shares of Common Stock at an exercise price of $8.91 per share, expiring September 14, 2036. Beginning on September 8, 2026, 1/48th of the option shares will vest in equal monthly installments over four years. No Rule 10b5-1 trading plan is reported for these awards.
Artiva Biotherapeutics, Inc. (ARTV) reported that its Chief Executive Officer, Fred Aslan, received equity awards on September 10, 2026. He was granted 155,000 stock options with an exercise price of $10.42 per share, expiring on September 9, 2036, and a separate award of 45,000 restricted stock units under the 2024 Equity Incentive Plan. Following the restricted stock unit grant, Aslan directly holds 1,494,765 shares of common stock. The stock options begin vesting on September 8, 2026 in equal monthly installments over four years. No Rule 10b5-1 trading plan is reported for these awards.
Artiva Biotherapeutics, Inc. (ARTV) reported an indirect acquisition of a director stock option related to board member Laura Stoppel. On September 10, 2026, an option for 16,250 shares of common stock was granted with an exercise price of $10.42 per share and no upfront cost. The option vests on the earlier of September 10, 2027 or the company’s 2027 annual stockholder meeting, subject to Dr. Stoppel’s continued board service, and expires on September 9, 2036. Under her arrangement with RA Capital entities, any net value from this option is turned over to those funds, and the reporting persons disclaim beneficial ownership.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Laura Stoppel received a grant of 16,250 Director Stock Options on September 10, 2026. The options have an exercise price of $10.42 per share and expire on September 9, 2036.
The options will vest in full on the earlier of September 10, 2027 or the date of Artiva’s 2027 annual stockholder meeting. According to the disclosure, Stoppel holds this option for the benefit of funds and an account managed by RA Capital Management, L.P. and disclaims beneficial ownership of the option and underlying common stock. No Rule 10b5-1 trading plan is reported.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Elaine K. Sorg received a stock option grant for 16,250 shares of common stock on September 10, 2026. The option has an exercise price of $10.42 per share, expires on September 9, 2036, and will vest in full on the earlier of September 10, 2027, or the company’s 2027 annual stockholder meeting. After this grant, she holds options for 16,250 shares directly, and no Rule 10b5-1 trading plan is reported.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Elizabeth L. Hougen received a grant of 16,250 director stock options on September 10, 2026. The options have an exercise price of $10.42 per share and expire on September 9, 2036. The award vests in full on the earlier of September 10, 2027, or the company’s 2027 annual stockholder meeting, and no Rule 10b5-1 trading plan is reported.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Brian Daniels received a grant of stock options for 16,250 shares of common stock on September 10, 2026. The options have an exercise price of $10.42 per share and expire on September 9, 2036.
The options vest in full on the earlier of September 10, 2027, or the date of Artiva Biotherapeutics, Inc.'s 2027 annual stockholder meeting. After this grant, Daniels holds stock options covering 16,250 shares directly. No Rule 10b5-1 trading plan is reported for this award.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Daniel G. Baker received a stock option grant on September 10, 2026 covering 16,250 shares of common stock at an exercise price of $10.42 per share. The option vests in full on the earlier of September 10, 2027 or the company’s 2027 annual stockholder meeting and expires on September 9, 2036.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Alison Moore received a grant of options to purchase 16,250 shares of common stock on September 10, 2026. The options have an exercise price of $10.42 per share and will vest in full on the earlier of September 10, 2027, or the company’s 2027 annual stockholder meeting, and expire on September 9, 2036. No Rule 10b5-1 trading plan is reported for this award.
Artiva Biotherapeutics, Inc. (ARTV) reported that President & Head of R&D Diego Miralles Gines received equity awards on September 9, 2026. He was granted options to purchase 135,000 shares of common stock at an exercise price of $10.79 per share, expiring September 8, 2036, and a separate grant of 45,000 restricted stock units under the 2024 Equity Incentive Plan. After these grants, he directly holds 122,500 shares of common stock and 135,000 option shares. No Rule 10b5-1 trading plan is reported.
Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Tech Operations Officer Christopher Horan received equity awards on September 9, 2026. He was granted 40,000 shares of Common Stock as a restricted stock unit award under the 2024 Equity Incentive Plan and options for 120,000 shares of Common Stock at an exercise price of $10.79 per share, expiring September 8, 2036. Following these awards, he directly holds 323,084 Common Shares and 120,000 stock options. The option award vests in equal monthly installments over four years, beginning September 8, 2026, and no Rule 10b5-1 trading plan is indicated.
Artiva Biotherapeutics, Inc. (ARTV) reported that officer Jennifer Bush, who serves as COO, CLO and Compliance Officer, received equity awards on September 9, 2026. She was granted options to buy 135,000 shares of common stock at an exercise price of $10.79 per share, expiring September 8, 2036, and a 45,000-share restricted stock unit award. Following these awards, she directly holds 374,529 shares of common stock, and the option begins vesting in equal monthly installments from September 8, 2026 over four years. No Rule 10b5-1 plan is reported for these awards.
Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Medical Officer Subhashis Banerjee received equity compensation on September 9, 2026. He was granted 30,000 shares of common stock as a restricted stock unit award under the company’s 2024 Equity Incentive Plan and now directly holds 170,947 common shares.
He was also granted 85,000 stock options to purchase common stock at an exercise price of $10.79 per share, expiring on September 8, 2036. Beginning on September 8, 2026, one forty-eighth of the option shares vests in equal monthly installments over four years. No Rule 10b5-1 trading plan is reported.
Artiva Biotherapeutics, Inc. (ARTV) reported that its Chief Executive Officer, Fred Aslan, sold 23,429 shares of common stock on September 8, 2026 in an open-market transaction under a Rule 10b5-1 Plan adopted on May 13, 2026. The weighted average sale price was $10.9158 per share, within a range of $10.72 to $11.13. Following this sale, the CEO directly holds 1,449,765 shares of Artiva common stock.
Artiva Biotherapeutics, Inc. (ARTV) reported that entities affiliated with RA Capital received an indirect interest in a stock option for 13,750 shares of Common Stock, granted to director Laura Stoppel on September 8, 2026 under the company’s non-employee director compensation policy at an exercise price of $10.88 per share. The option vests on the earlier of September 8, 2027 or the date of Artiva’s 2027 annual stockholder meeting, and expires on September 7, 2036, subject to Dr. Stoppel’s continuous service as a director. Under Dr. Stoppel’s arrangement with RA Capital’s adviser, any net cash or stock from exercising the option will benefit RA Capital funds and a separately managed account, and the reporting persons disclaim beneficial ownership except to the extent of any pecuniary interest; no Rule 10b5-1 trading plan is reported.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Laura Stoppel received a grant of 13,750 stock options on September 8, 2026. These options have an exercise price of $10.88 per share and become fully vested on the earlier of September 8, 2027, or the company’s 2027 annual stockholder meeting. The options expire on September 7, 2036, and no Rule 10b5-1 trading plan is reported for this grant.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Elaine K. Sorg received a grant of 13,750 director stock options on September 8, 2026. The options have an exercise price of $10.88 per share and expire on September 7, 2036. According to the award terms, all shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of Artiva Biotherapeutics, Inc.'s 2027 annual stockholder meeting. Following this grant, Sorg holds 13,750 options directly.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Elizabeth L. Hougen received a grant of 13,750 Director Stock Options on September 8, 2026. The options have an exercise price of $10.88 per share and will vest in full on the earlier of September 8, 2027 or the company’s 2027 annual stockholder meeting. Following this grant, she holds 13,750 options directly, expiring on September 7, 2036; no Rule 10b5-1 trading plan is reported.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Brian Daniels received a grant of options to purchase 13,750 shares of Common Stock on September 8, 2026. The options have an exercise price of $10.88 per share and expire on September 7, 2036.
These options will vest in full on the earlier of September 8, 2027, or the date of Artiva’s 2027 annual stockholder meeting, and Daniels now holds 13,750 option shares directly after this grant. No Rule 10b5-1 trading plan is reported for this award.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Daniel G. Baker received a stock option award for 13,750 shares of common stock on September 8, 2026. The option has an exercise price of $10.88 per share and expires on September 7, 2036.
The option vests in full on the earlier of September 8, 2027 or the date of Artiva Biotherapeutics’ 2027 annual stockholder meeting, and following this grant Baker holds 13,750 option shares directly.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Alison Moore received a grant of 13,750 stock options on September 8, 2026. The options have an exercise price of $10.88 per share, expire on September 7, 2036, and vest in full on the earlier of September 8, 2027, or the company’s 2027 annual stockholder meeting. No Rule 10b5-1 trading plan is reported for this grant.
Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Tech Operations Officer Christopher Horan sold 10,366 shares of common stock on September 3, 2026, at a weighted average price of $11.1555 per share. According to the company’s sell-to-cover policy, these automatic sales were made solely to satisfy tax withholding obligations from vesting restricted stock units, and Horan held 283,084 shares directly after the transaction.
Artiva Biotherapeutics, Inc. (ARTV) reported that officer Jennifer Bush, the company's COO, CLO and Compliance Officer, sold 8,391 shares of common stock on September 3, 2026. The company states these sales were automatic sell-to-cover transactions for tax withholding on vesting restricted stock units, not discretionary trades, leaving her with 329,529 shares held directly.
Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Medical Officer Subhashis Banerjee sold 1,100 shares of common stock on September 3, 2026 at $11.1556 per share. According to the company’s sell-to-cover policy, this automatic sale was made solely to cover tax withholding from vested restricted stock units, and Banerjee now holds 140,947 shares directly.
Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Executive Officer Fred Aslan sold 61,888 shares of common stock on September 3, 2026 at a weighted average price of $11.1555 per share. The company states these automatic sales were made solely to cover tax withholding on vested restricted stock units, under a corporate sell-to-cover policy. Following the transaction, Aslan directly held 1,473,194 shares of Artiva common stock.
Artiva Biotherapeutics, Inc. (ARTV) reported insider transactions by Chief Medical Officer Subhashis Banerjee on August 27, 2026. Banerjee exercised 5,306 stock options at $1.92 per share to acquire the same number of common shares, then sold 8,222 common shares at a weighted average of $12.0087 per share. The option exercise left 74,265 options outstanding and was carried out under a Rule 10b5-1 trading plan adopted on May 14, 2026.
Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Medical Officer Subhashis Banerjee exercised employee stock options for 429 shares of common stock at an exercise price of $1.92 per share and immediately sold 429 shares of common stock at $12.00 per share on 2026-08-18. Following the option exercise, Banerjee held 79,571 stock options. The transactions occurred pursuant to a Rule 10b5-1 Plan adopted on May 14, 2026. The option grant vested 25% on April 8, 2026, with the remaining shares vesting monthly over the following 36 months.
RA Capital Management-affiliated investment vehicles reported open-market purchases of 45,768 shares of Artiva Biotherapeutics common stock. On July 29, 2026 they bought 20,824 shares at a weighted average price of $9.99, and on July 31 they bought 24,944 shares at $9.93.
The shares are held indirectly through RA Capital-managed funds and a separately managed account, and the adviser and related parties disclaim beneficial ownership beyond their pecuniary interests. A partner of the adviser serves on Artiva’s board, providing board representation for these investors.
RA Capital Management, L.P. and affiliated funds reported purchasing 41,319 shares of Artiva Biotherapeutics, Inc. common stock on July 24, 2026 at a weighted average price of $9.99 per share, with trades between $9.96 and $10.00, held indirectly by RA Capital Healthcare Fund LP. The Adviser, its general partner, and Dr. Peter Kolchinsky and Mr. Rajeev Shah act as investment manager and managing members and disclaim beneficial ownership except to the extent of their pecuniary interest; additional Artiva shares are held through RA Capital Nexus funds and a separately managed account under similar terms.
RA Capital Healthcare Fund LP, advised by RA Capital Management, reported open-market purchases of 264,586 shares of Artiva Biotherapeutics common stock on July 21–23, 2026, at weighted average prices of $9.55, $9.93, and $9.96 per share. The RA Capital entities and principals disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
Entities affiliated with RA Capital Management, L.P., significant stockholders and directors of Artiva Biotherapeutics, Inc., purchased 6,522 shares of common stock on July 13, 2026 at a weighted-average price of $8.94 per share (range $8.89–$8.95). Following this indirect purchase, the RA Capital funds reported holding 16,817,543 shares of Artiva common stock. The amendment corrects an earlier Form 4 share count, and notes the shares are held by RA Capital Healthcare Fund, L.P., with the Adviser and related parties disclaiming beneficial ownership except to the extent of their pecuniary interests.
Artiva Biotherapeutics, Inc. reported indirect insider purchases by RA Capital–managed entities. On July 16, 2026, they purchased 152,472 common shares in open-market or private transactions at a weighted average price of $8.93 per share, with individual prices from $8.79 to $9.00. On July 17, 2026, they purchased 7,882 shares at a weighted average price of $8.95, with trades between $8.88 and $9.00.
The shares are held directly by RA Capital Healthcare Fund, RA Capital Nexus Fund, RA Capital Nexus Fund III and a separately managed account for which RA Capital Management, L.P. acts as investment manager. RA Capital, its general partner and principals, including Dr. Peter Kolchinsky and Mr. Rajeev Shah, disclaim beneficial ownership beyond their pecuniary interest. The trades were not reported as made under a Rule 10b5-1 plan.
Entities affiliated with RA Capital Management reported open-market purchases of a total of 21,654 shares of Artiva Biotherapeutics common stock on 2026-07-10 and 2026-07-13 at weighted-average prices of $8.9700 and $8.9400 per share. After these trades they report 16,817,573.0000 shares of common stock held indirectly across several managed funds and a separately managed account, while disclaiming beneficial ownership beyond their pecuniary interests.
Artiva Biotherapeutics, Inc. disclosed that investment vehicles managed by RA Capital Management, L.P. made net open-market purchases of 32,876 shares of its common stock. On June 25, 2026, a fund associated with RA Capital bought 31,000 shares at a weighted average price of $8.88 per share, and on June 26, 2026, a related account bought 1,876 shares at a weighted average price of $8.98 per share. Footnotes state these trades occurred in multiple transactions within price ranges of $8.62–$8.98 and $8.97–$9.00. After these transactions, RA Capital–managed entities collectively report indirect holdings in several blocks, including 16,795,919 shares in one fund, reflecting a large existing position with a relatively small incremental purchase.
Artiva Biotherapeutics, Inc. reported open-market purchases of its common stock by investment funds and accounts managed by RA Capital Management, L.P. The transactions covered a total of 531,326 shares at prices around $8.57 to $8.99 per share, with weighted-average prices within disclosed ranges of $8.31 to $9.00. Following these buys, the largest reported indirect position among the reporting entities was 16,763,043 shares of common stock. The Adviser, its general partner and related individuals and funds disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
Artiva Biotherapeutics, Inc. insider filing shows affiliated RA Capital funds buying additional common stock in open-market transactions. Entities managed by RA Capital purchased a total of 1,027,722 Artiva shares between June 9 and June 11, 2026 at prices around $6.91–$7.91 per share.
After these indirect purchases through RA Capital-managed vehicles, the reporting group is shown holding 16,231,717 shares of Artiva common stock. Footnotes state the adviser and related parties disclaim beneficial ownership except to the extent of their pecuniary interest.
GC Corp. and subsidiary GC Cell Corporation, both 10% owners of Artiva Biotherapeutics, Inc., bought a combined 1,432,291 shares of Artiva common stock in open‑market transactions. The purchases were made on May 11, 2026 at $11.52 per share.
After these transactions, GC Cell Corporation held 1,607,734 Artiva shares indirectly and GC Corp. held 4,391,969 shares directly. Footnotes explain that GC Corp. is a Korean holding company ultimately controlled by its board, whose members may be deemed to share voting and investment power but each disclaims beneficial ownership except for any pecuniary interest.
Artiva Biotherapeutics, Inc. senior vice president of research and development Heather Raymon reported an open-market sale of 3,095 shares of common stock at a weighted average price of $9.0078 per share. According to the company’s sell-to-cover policy, these shares were sold automatically to satisfy tax withholding on vested restricted stock units. After this transaction, Raymon directly holds 148,228 Artiva shares.
Artiva Biotherapeutics, Inc. reported that Chief Tech Operations Officer Christopher Horan sold 7,002 shares of common stock on May 19, 2026 at a weighted average price of $9.0078 per share. The price range for these sales was between $8.7421 and $9.0104.
According to the company’s sell-to-cover policy, these automatic sales were made solely to cover tax withholding obligations arising from the vesting and release of restricted stock units, and were not discretionary trades. After the transaction, Horan directly owned 293,450 shares of Artiva common stock.
Artiva Biotherapeutics COO Jennifer Bush reported an automatic sale of 8,790 common shares to cover tax withholding on vested restricted stock units. The shares were sold in the open market at a weighted average price of $9.0078 per share, within a range of $8.7439 to $9.0104. After this sell-to-cover transaction under the company’s tax policy, she continues to hold 337,920 shares directly.
Artiva Biotherapeutics' Chief Medical Officer, Subhashis Banerjee, sold 7,037 shares of common stock in an open-market transaction at a weighted average price of $9.0076 per share. The company explains these automatic sales were made solely to cover tax withholding obligations tied to vested restricted stock units. Following the sale, Banerjee directly holds 144,963 shares.
Artiva Biotherapeutics, Inc. Chief Executive Officer Fred Aslan reported an open-market sale of 27,116 shares of common stock at a weighted average price of $9.0077 per share. After this transaction, he directly holds 1,535,082 shares.
The company has a “sell-to-cover” policy for tax withholding on vesting restricted stock units, and these shares were sold automatically to cover related tax obligations, not at Aslan’s discretion. Sale prices ranged between $8.7383 and $9.0104.
Artiva Biotherapeutics President & Head of R&D Diego Miralles received new equity awards. He was granted 77,500 shares of common stock as restricted stock units and 232,500 employee stock options with an exercise price of $9.22 per share under the company’s 2025 Inducement Plan.
Following the grants, he directly holds 77,500 shares of common stock and 232,500 options. According to the award terms, 25% of the option shares vest on May 15, 2027, with the remaining shares vesting monthly over the next 36 months.
Artiva Biotherapeutics received a large indirect equity investment from RA Capital–affiliated entities. On May 11, 2026, RA Capital–managed vehicles reported open‑market purchases of 6,510,416 shares of Artiva common stock at $11.52 per share and 2,170,138 Pre-Funded Warrants at $11.5199 per warrant.
Following these trades, the reporting entities indirectly held 15,203,995 shares of common stock and 2,170,138 Pre-Funded Warrants, along with additional indirect common stock positions of 68,320, 826,832, and 264,571 shares through various RA Capital funds and a separately managed account.
The filing states that RA Capital Management, its general partner, and principals disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest. The Pre-Funded Warrants are exercisable immediately, but the Fund cannot exercise them if doing so would push its beneficial ownership above 9.99% of Artiva’s outstanding common stock.
Huston Thad Allen reported acquisition or exercise transactions in this Form 4 filing.
Artiva Biotherapeutics’ Chief Financial Officer, Thad Allen Huston, received an equity award of 220,000 shares of common stock on March 10, 2026. The Form 4 describes this as a restricted stock unit grant under the company’s 2025 Inducement Plan, with no cash purchase price and resulting direct ownership of 220,000 shares.